University of Notre Dame du Lac’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

University of Notre Dame du Lac’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-759,949	Closed	-$12M	–	65
2019 Q2	$12M	Buy	759,949 +518,836	+215%	+$7.06M	2.72%	6
2019 Q1	$3.53M	Buy	241,113 +70,379	+41%	+$809K	0.79%	42
2018 Q4	$1.82M	Buy	+170,734	New	+$2.25M	0.44%	64

Other funds holding DRNA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

University of Notre Dame du Lac's DRNA Position: Q3 2019 in Review

University of Notre Dame du Lac sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2019, closing a stake of 759,949 shares — an estimated $12M sold.

University of Notre Dame du Lac first reported a position in DRNA in Q4 2018 and held it in 3 quarters. The position peaked at $12M in Q2 2019. 112 funds tracked by Wall St. Rank hold DRNA as of Q3 2019.

University of Notre Dame du Lac reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
University of Notre Dame du Lac sold 759,949 Dicerna Pharmaceuticals, Inc. shares in Q3 2019, an estimated $12M.
University of Notre Dame du Lac first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2018 and held it in 3 quarters.
University of Notre Dame du Lac's Dicerna Pharmaceuticals, Inc. position peaked at $12M in Q2 2019.
112 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2019.

Based on University of Notre Dame du Lac's 13F filing for Q3 2019, filed 13 Nov 2019.